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To the Editor: 21 
In December 2019, cases of pneumonia of unknown origin were reported in Wuhan, Hubei, 22 
China.[1] Investigations showed that the cause was a novel RNA virus belonging to the 23 
Coronaviridae family. Since the first reported cases, the disease, termed Corona virus disease 24 
2019 (COVID-19), has spread widely resulting in the World Health Organization, on January 30 25 
2020, declaring COVID-19 a Public Health Emergency of International Concern.[2]  26 
As of the last week of March 2020, many countries are under lockdown, medical services are 27 
changing priorities and policies, and health care resources have been shifted to focus on outbreak 28 
management. These new circumstances, which continue to evolve, may impact negatively on the 29 
treatment of other diseases. Of particular interest is the effect on oncology patients,[3] and more 30 
specifically pediatric oncology patients,[4] where disease poses a threat to life.   31 
Retinoblastoma is the most common ocular malignancy of childhood.[5] Early diagnosis and 32 
treatment have improved the prognosis for children with retinoblastoma in high income countries 33 
now reaching >90% disease-free survival rate.[6, 7] We aimed to investigate the impact of the 34 
COVID-19 pandemic on retinoblastoma management in treatment centers across the world, and 35 
indirectly on patients’ prognosis. This information is important for policy and healthcare 36 
planning at national and international levels, during the pandemic, and for better preparation in 37 
future.   38 
A survey focusing on retinoblastoma management during the pandemic was sent on March 29 39 
2020 to members of the Global Retinoblastoma Study Group.[8] Participants were asked to 40 
return the completed survey before April 4 2020. During this week, daily COVID-19 data at 41 
country and global levels were retrieved from the World Health Organization database.[9]  42 
Overall, 194 centers from 94 countries were included in the analysis. Of the participating centers, 43 
73 (37.6%) were from Asia, 34 (17.5%) from Europe, 40 (20.6%) from Africa, 6 (3.1%) from 44 
Australasia, 17 (8.8%) from Latin America and the Caribbean, and 24 (12.4%) from North 45 
America.  46 
Globally, the total number of COVID-19 positive patients reported on March 29 and April 4 47 
2020, respectively, was 723,390 and 1,201,483, and reported deaths were 34,065 and 64,690. 48 
The total number of reported COVID-19 positive patients in the 94 participating countries on 49 
March 29 and April 4 2020, respectively, was 702,559 (97.1%) and 1,165,380 (97.0%), and 50 
reported deaths were 33,660 (98.8%) and 63,720 (98.5%) (Figure 1).  51 
Supplemental Table S1 shows the COVID-19 data per participating country during the study 52 
period, data on travel restrictions, and policy for retinoblastoma patients. In 51 countries 53 
(54.3%), there were less than 100 COVID-19 positive cases per average day, in 30 countries 54 
(31.9%) there were between 100 and 999 new positive cases, and in 9 (9.6%) countries there 55 
were between 1,000 and 10,000 new positive cases per day. In terms of deaths, no cases were 56 
reported in 23 (24.5%) of the participating countries, in 50 (53.2%) countries there were 1 to 9 57 
deaths per day on average, and in 17 (18.1%) countries there were between 10 and 499 deaths 58 
per day on average. In France, Italy, Spain and the USA there were 500-1000 new deaths, on 59 
average per day in each country.  60 
Of the 194 participating centers, 82 (42.3%) reported that families are restricted from travelling 61 
to the retinoblastoma center. Most centers (170 (87.7%)) reported that they accept new referrals 62 
for examination and treatment, and most (185 (95.4%)) reported that they continue treating 63 
active cases. Of the 194 participating centers, 112 (57.7%) reported a policy of deferring stable 64 
cases. Six (3.1%) centers reported that they are not providing any services.  65 
Overall, 16 (8.3%) centers reported that retinoblastoma management was disrupted due to 66 
personnel being quarantined or sick (i.e. COVID-19 positive), 11 (5.7%) due to personnel being 67 
needed elsewhere, 7 (3.6%) due to equipment being needed elsewhere/missing, 40 (20.6%) due 68 
to a combination of factors, and 120 (61.9%) reported no disruption.  69 
Table 1 shows the modalities available in treatment centers before and during the pandemic. 70 
Examinations under anesthesia (EUAs), enucleation, intravenous chemotherapy (IVC) and intra-71 
arterial chemotherapy (IAC) were available in 186 (95.9%), 193 (100.0%), 187 (96.9%) and 96 72 
(49.7%), respectively, of the centers before the outbreak. During the pandemic, EUAs were fully 73 
available in 107 (55.2%) of the centers. In terms of treatment modalities, enucleation was 74 
available in 173 (89.6%), IVC in 181 (93.8) and IAC in 73 (37.8) of the centers.  75 
Overall, 104 (53.6%) of the centers have reported that changes and restrictions outside or within 76 
the center due to the COVID-19 pandemic are potentially affecting the lives of retinoblastoma 77 
patients. A summary of the impact of the COVID-19 pandemic on retinoblastoma management 78 
as reported by the participating centers is shown in https://retinoblastoma.world/.  79 
Findings of the present survey indicate that, according to most centers, changes and restrictions 80 
related to the COVID-19 pandemic potentially risk the lives of retinoblastoma patients. 81 
Approximately 40% of the participating centers reported that families are restricted from 82 
reaching a retinoblastoma center. Moreover, nearly 40% of centers reported disruption in 83 
retinoblastoma management during the outbreak related to personnel or equipment.  84 
Enucleation can save lives. IVC can save lives and result in globe salvage when patients are 85 
diagnosed and treated before extraocular spread.[10, 11] During the study period, most centers 86 
were able to continue to provide these life-saving treatment modalities. Conversely, availability 87 
of IAC reduced to just over one third of the centers from about half of the centers pre-COVID-88 
19.  Whilst IAC can be useful for globe salvage,[12] as a treatment modality it is not as critical 89 
as IVC or enucleation surgery for survival. However, continued provision of any treatment 90 
modalities is irrelevant if patients are precluded from reaching the treatment center.  91 
In summary, findings of the present survey from 194 treatment centers, which was conducted 92 
while the pandemic escalates across the world, indicate that, globally, management of children 93 
with retinoblastoma is compromised, jeopardizing their lives. There is a delicate balance of risk 94 
management during a global pandemic. Treating patients, especially children, with a highly 95 
curable disease but potentially fatal when no treatment is delivered, remains a priority even in the 96 
face of a dangerous global viral outbreak. Decision makers should be aware of the effects of 97 
broad sweeping policies and take them into account when weighing all the risks and benefits of 98 
the situation. 99 
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Figure 1 155 
Covid-19 positive cases (A) and deaths cases (B) in 94 countries as of April 4 2020 (end of 156 
survey).  157 
